What one share of Atossa Therapeutics holds
We are a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and other breast conditions. Our lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator (SERM)/ selective estrogen receptor degrader (SERM/D) currently in Phase 2 clinical development.
Atossa Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.34 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$4.12 |
| Cash and investments | $2.61 |
| Book value | $2.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | $0.17 | −$1,497 | — | — | — | $309.35 |
| 2016 | — | −$388.97 | — | — | — | $147.21 |
| 2017 | — | −$164.51 | — | — | — | — |
| 2018 | — | −$82.56 | $0.40 | −$32.73 | — | $22.59 |
| 2019 | — | −$30.43 | $0.01 | −$16.13 | — | $21.61 |
| 2022 | — | −$3.19 | $0.00 | −$2.46 | — | $13.97 |
| 2023 | — | −$3.58 | $0.00 | −$2.49 | — | $10.90 |
| 2024 | — | −$3.04 | $0.00 | −$2.51 | — | $8.30 |
| 2025 | — | −$4.04 | $0.00 | −$3.46 | — | $4.57 |
Common questions about Atossa Therapeutics
How much does one share of Atossa Therapeutics earn?
Over the last 12 months, Atossa Therapeutics lost $4.34 for each share.
Does Atossa Therapeutics pay a dividend?
Atossa Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Atossa Therapeutics’s book value per share?
Atossa Therapeutics’s book value is $2.69 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Atossa Therapeutics have?
Each share of Atossa Therapeutics has $2.61 of cash and investments, as of June 30, 2026.
What is Atossa Therapeutics’s free cash flow per share?
−$4.12 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Atossa Therapeutics bought back shares?
Atossa Therapeutics’s share count rose about 81689% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.